Disposition of tradable shares by Garg Pushkal of Alnylam Pharmaceuticals at 255.8 subject to Rule 16b-3
ALNY Stock | USD 237.98 2.57 1.07% |
Slightly above 55% of Alnylam Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Alnylam Pharmaceuticals suggests that many traders are impartial. Alnylam Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Alnylam Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Alnylam |
Filed transaction by Alnylam Pharmaceuticals Officer: Cmo & Evp Dev & Med Affairs. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at statnews.com
Alnylam Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Alnylam Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Alnylam Pharmaceuticals Maximum Pain Price Across March 21st 2025 Option Contracts
Alnylam Pharmaceuticals' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Alnylam Pharmaceuticals close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Alnylam Pharmaceuticals' options.
Alnylam Pharmaceuticals Fundamental Analysis
We analyze Alnylam Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Alnylam Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Alnylam Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Alnylam Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Alnylam Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Alnylam Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Alnylam Pharmaceuticals Related Equities
EXEL | Exelixis | 4.41 | ||||
MDGL | Madrigal Pharmaceuticals | 1.66 | ||||
UTHR | United Therapeutics | 0.45 | ||||
BMRN | Biomarin Pharmaceutical | 1.46 | ||||
HALO | Halozyme Therapeutics | 1.79 | ||||
KRYS | Krystal Biotech | 2.39 | ||||
DAWN | Day One | 3.28 | ||||
BPMC | Blueprint Medicines | 3.53 | ||||
INCY | Incyte | 3.54 | ||||
RARE | Ultragenyx | 3.62 | ||||
AMLX | Amylyx Pharmaceuticals | 7.16 | ||||
PRQR | ProQR Therapeutics | 7.63 | ||||
WVE | Wave Life | 7.68 | ||||
APLS | Apellis Pharmaceuticals | 16.85 |
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.